aid: latigo-bio
name: Latigo Bio
description: 'Latigo Biotherapeutics, Inc. ("Latigo Bio") is a clinical-stage biotechnology
  company headquartered in Thousand Oaks, California, developing novel non-opioid medicines
  for acute and chronic pain. Its lead candidates LTG-001 and LTG-321 are oral NaV1.8
  sodium-channel inhibitors targeting pain at its peripheral source without the addiction
  risk of opioids; LTG-001 holds FDA Fast Track designation and reported positive Phase 2b
  results in post-abdominoplasty acute pain, published in the New England Journal of
  Medicine in July 2026. The company was founded on human-genetics-validated targets and
  uses in-house AI/ML and structure-based drug design to optimize potency and selectivity.
  It debuted in 2024 with a $135M Series A and closed a $150M Series B in March 2025, backed
  by Westlake Village BioPartners, 5AM Ventures, Foresite Capital and Corner Ventures.
  Latigo is a therapeutics developer, not a software vendor: it publishes no public API,
  developer portal, SDK or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/latigo-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-harvest-listing: https://forgeglobal.com/latigo-bio_stock/
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Clinical Trials
- Healthcare
- Pain Management
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/latigo-bio-domain-security.yml
- type: Website
  url: https://latigobio.com/
- type: TermsOfService
  url: https://latigobio.com/terms-of-use/
- type: PrivacyPolicy
  url: https://latigobio.com/privacy-policy/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Latigo Biotherapeutics is a clinical-stage drug developer whose product is a molecule
    (oral NaV1.8 inhibitors LTG-001/LTG-321), not software — it runs no developer program:
    api., developer., docs., dev., portal., app. and data.latigobio.com are all NXDOMAIN,
    github.com/latigobio and /LatigoBiotherapeutics 404, and the corporate site itself sits
    behind a SiteGround robot challenge that answers HTTP 202 with an identical challenge
    shell to every path, including all eight /.well-known/* probes.
  evidence:
  - url: https://latigobio.com/openapi.json
    status: 202
  - url: https://latigobio.com/.well-known/agent-card.json
    status: 202
  - url: https://github.com/latigobio
    status: 404
  - url: https://registry.npmjs.org/latigobio
    status: 404
  checked: '2026-08-23'